Jacobs Levy Equity Management, Inc Tricida, Inc. Transaction History

Jacobs Levy Equity Management, Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$8.51 - $13.6 $1.7 Million - $2.72 Million	200,038 Added 259.62%	277,089 $2.9 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $2.5 Million - $4.06 Million	-342,554 Reduced 81.64%	77,051 $746,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $22,946 - $33,186	3,122 Added 0.75%	419,605 $3.45 Million
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $551,559 - $1.26 Million	-131,637 Reduced 24.02%	416,483 $3.98 Million
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $1.05 Million - $1.36 Million	-294,006 Reduced 34.91%	548,120 $2.54 Million

Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $595,956 - $816,233	150,875 Added 21.83%	842,126 $3.64 Million
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $2.18 Million - $3.77 Million	483,353 Added 232.5%	691,251 $3.66 Million
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $31,800 - $68,840	-7,277 Reduced 3.38%	207,898 $1.47 Million
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $266,113 - $837,199	31,088 Added 16.89%	215,175 $1.95 Million
Q2 2020 Aug 17, 2020	BUY	$21.21 - $31.55 $3.9 Million - $5.81 Million	184,087 New	184,087 $5.06 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.